Cantor Fitzgerald Reiterates Neutral Rating on Eagle Pharmaceuticals (EGRX) Following Response to COVID-19
Tweet Send to a Friend
Cantor Fitzgerald analyst Brandon Folkes reiterated a Neutral rating and $46.00 price target on Eagle Pharmaceuticals (NASDAQ: EGRX). On 4/16/2020 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
